CG Oncology, Inc. - Common stock (NQ:CGON)

67.38 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 28, 2025

Via Benzinga

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook ↗

April 28, 2025

Via Benzinga

Which stocks are gapping on Monday? ↗

April 28, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why ↗

April 28, 2025

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025.

Via Benzinga

3 Analysts Assess CG Oncology: What You Need To Know ↗

March 07, 2025

Via Benzinga

Why CG Oncology (CGON) Stock Is Down 9% ↗

December 11, 2024

CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock.

Via Benzinga

Demystifying CG Oncology: Insights From 7 Analyst Reviews ↗

December 06, 2024

Via Benzinga

These stocks are moving in today's pre-market session ↗

April 28, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗

April 28, 2025

Via Benzinga

CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug ↗

April 28, 2025

The companies are working on treatments for a form of bladder cancer.

Via Investor's Business Daily

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings ↗

April 28, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 28, 2025

Via Benzinga

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

April 26, 2025

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

April 24, 2025

From CG Oncology Inc.

Via GlobeNewswire

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

April 16, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

April 11, 2025

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

March 31, 2025

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

March 28, 2025

From CG Oncology Inc.

Via GlobeNewswire

Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts ↗

March 25, 2025

Via Benzinga

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

March 24, 2025

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

March 12, 2025

Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented

From CG Oncology Inc.

Via GlobeNewswire

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug ↗

March 06, 2025

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.

Via Benzinga

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

February 26, 2025

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 16, 2024

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Announces Pricing of Public Offering

December 12, 2024

From CG Oncology Inc.

Via GlobeNewswire

Nasdaq Jumps 300 Points To Record Highs ↗

December 11, 2024

Stocks are higher this afternoon, after this morning's highly-anticipated CPI report met expectations.

Via Talk Markets

Topics Stocks / Equities

CG Oncology Announces Proposed Public Offering

December 11, 2024

From CG Oncology Inc.

Via GlobeNewswire

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

December 06, 2024

Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate ↗

December 05, 2024

CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients, with median DOR exceeding 27 months and no severe side effects.

Via Benzinga

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

December 05, 2024

From CG Oncology Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.